If larger trials succeed, personalized mRNA vaccines could finally turn pancreatic cancer from a near-certain killer into a ...
Ben Sasse (R–Neb.), who previously served as president of the University of Florida, revealed in late December that he had ...
The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...
An mRNA vaccine for pancreatic cancer is showing long-term results in an early-stage clinical trial. Still in its ...
The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...
Pancreatic cancer treatment may see a breakthrough with a personalized mRNA vaccine demonstrating the ability to create ...
ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call ...
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results